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Abstract
Background: A Disintegrin And Metalloprotease (ADAM) 9 has been implicated in tumour
progression of various solid tumours, however, little is known about its role in renal cell carcinoma.
We evaluated the expression of ADAM9 on protein and transcript level in a clinico-pathologically
characterized renal cell cancer cohort.
Methods: 108 renal cancer cases were immunostained for ADAM9 on a tissue-micro-array. For
30 additional cases, ADAM9 mRNA of microdissected tumour and normal tissue was analyzed via
quantitative RT-PCR. SPSS 14.0 was used to apply crosstables (Fisher's exact test and χ2-test),
correlations and univariate as well as multivariate survival analyses.
Results: ADAM9 was significantly up-regulated in renal cancer in comparison to the adjacent
normal tissue on mRNA level. On protein level, ADAM9 was significantly associated with higher
tumour grade, positive nodal status and distant metastasis. Furthermore, ADAM9 protein
expression was significantly associated with shortened patient survival in the univariate analysis.
Conclusion: ADAM9 is strongly expressed in a large proportion of renal cell cancers, concordant
with findings in other tumour entities. Additionally, ADAM9 expression is significantly associated
with markers of unfavourable prognosis. Whether the demonstrated prognostic value of ADAM9
is independent from other tumour parameters will have to be verified in larger study cohorts.
Background
Renal cell cancer (RCC) is thought to cause 12.890 deaths
in 2007 in the USA [1] and accounts for around 2–3% of
cancers worldwide [2,3]. It is one of the most lethal uro-
logic malignancies. Nodal and systemic metastasis as well
as vascular invasion are important prognostic factors in
this tumour entity [4]. New molecular markers are war-
ranted to improve the classification of RCC, to provide
further prognostic and predictive information and eventu-
ally to allow for an individualized cancer therapy [5-8].
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In this study, we focused on ADAM9 (synonyms: MDC9,
meltrin-γ), a member of the "A Disintegrin And Metallo-
protease" family. Functionally, ADAMs participate in
spermatogenesis, cell adhesion, myo- and neurogenesis,
inflammation, cell migration and tissue remodelling
[9,10]. ADAMs are membrane-anchored cell surface glyc-
oproteins with a protease domain in addition to an adhe-
sion domain. The structure of ADAMs was found to be
related to soluble snake venom proteins which induce
hemorrhage and basement membrane destruction
[11,12]. The interactions of ADAMs with cell surface and
extracellular matrix proteins like integrins and syndecans
could be of relevance in tumour biology as these processes
are vital for tumour progression defined by growth, inva-
sion and metastasis [13-17]. Several ADAMs have been
analyzed in various tumour entities and were often found
to be differentially expressed, partially conveying prog-
nostic information [18-32]. Several ADAMs have already
been shown up-regulated in renal cancer on transcript
level, with ADAM8 being associated with shortened sur-
vival times and distant metastasis [33,34].
ADAM9 has been proposed to be involved in the ectodo-
main shedding of membrane-anchored of heparin-bind-
ing epidermal growth factor-like growth factor, probably
regulated by the binding protein Eve-1 [35-37]. Possible
mediating effects on EGFR activity further support the
notion of ADAM9 involvement in carcinogenesis and
tumour progression [38,39,35,40,41]. Moreover, ADAM9
promotes cancer cell invasion by modifying or regulating
e-cadherin and several types of integrins [21,42].
We evaluated the ADAM9 expression on protein and tran-
script level to clarify a diagnostic or prognostic value of
ADAM9 in renal cell cancer. We found ADAM9 mRNA up-
regulated in RCC and demonstrated a prognostic value of
ADAM9 protein expression for overall survival times.
Methods
Patients (RT-PCR)
Thirty matched malignant and non-malignant kidney tis-
sue samples were derived from patients (26 male, four
female; mean age 62 years, range: 40 to 92 years) with
clear cell (cc) RCC undergoing radical nephrectomy at the
Department of Urology, Charité – Universitätsmedizin
Berlin, between September 2003 and January 2006.
Cases used for mRNA isolation were different from the
cohort used for immunohistochemistry. Thirteen of the
30 ccRCC were pT1 stage, two tumours were pT2, and 15
tumours were pT3. Histological grading: G1 (n = 3), G2 (n
= 25) and G3 (n = 2). None of the patients had known
nodal or distant metastasis according to preoperative
screening (computed tomography of chest, abdomen and
pelvis). Samples were collected immediately after surgery
in tubes with RNAlater® Stabilization Reagent (Qiagen,
Hilden, Germany). Until RNA isolation the tubes were
stored at 4°C overnight and then at -80°C until analysis.
Patients (immunohistochemistry)
One-hundred-eight patients (83 men, 25 women) diag-
nosed for renal cancer at the Institute of Pathology, Char-
ité – Universitätsmedizin Berlin between 2003 and 2005
were enclosed in this study. The study has been approved
by the Charité University Ethics Committee under the title
'Retrospektive Untersuchung von Gewebeproben mittels
immunhistochemischer Färbung und molekularbiolo-
gischer Methoden' ('Retrospective analysis of tissue sam-
ples by immunohistochemistry and molecular biological
techniques') (EA1/06/2004) on 20 September 2004.
Patient age ranged between 28 and 92 years with a median
of 62. Histological diagnosis was established according to
the guidelines of the World Health Organization. Cases
were selected according to tissue availability and were not
stratified for any known preoperative or pathological
prognostic factors. Eightysix (79.6%) patients had a clear
cell RCC (ccRCC), 17 (15.7%) a papillary RCC and five
(4.6%) a chromophobe RCC. Twentythree patients had
systemic disease (pM1) at the time of diagnosis. Tumour
specific survival times, as annually assessed, was available
for all patients. The median follow-up time of all cases
was 30 months, ranging from one to 47 months. Twenty-
three patients died from renal cancer. The pT stages: 54
(50.0%) pT1, 3 (2.8%) pT2, 47 (43.5%) pT3 and 4 (3.7%)
pT4. Twelve patients (11.1%) had pathologically con-
firmed nodal metastases (pN1 = 3, pN2 = 9). Fiftyone
(47.2%) patients had no nodal metastases (pN0). Of 45
(41.7%) patients no lymph nodes were histologically
examined (pNx). Hemangiosis carcinomatosa (V1/2) was
detected in 29 (26.8%) cases. Tumour grades: 11 (10.2%)
G1, 75 (69.4%) G2, 18 (16.7%) G3 and 4 (3.7%) G4. The
sample cohort for the immunohistochemical study was
different from the sample cohort used for mRNA analysis.
The grouped clinico-pathological data of the immunohis-
tochemically analysed cases are described in the left col-
umns of Table 1.
Tissue micro array construction
A tissue micro array (TMA) was constructed as previously
described [43]. Briefly, suitable areas for tissue retrieval
were marked on standard haematoxylin/eosin (H&E) sec-
tions, punched out of the paraffin block and inserted into
a recipient block. The tissue arrayer was purchased from
Beecher Instruments (Woodland, USA). The punch diam-
eter was 0.6 mm. The RCC array was constructed to repre-
sent 109 cases with two spots from the tumour and two
spots representing matching normal tissue from the cortex
region of the kidney. In four cases, the normal spots did
not represent kidney tissue, leaving 105 cases withBMC Cancer 2008, 8:179 http://www.biomedcentral.com/1471-2407/8/179
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matched tumour and normal tissue, plus four cases with
tumour only. The whole TMA was accomplished on three
paraffin blocks.
RNA Isolation
Total RNA was isolated from 50 mg RNAlater™ stabilised
kidney tissue samples using the RNeasy Mini Kit (Qiagen)
according to the manufacturer's instructions. Addition-
ally, we introduced a DNase I (Qiagen) digestion step on
the silica gel membrane of the spin column where the
RNA was bound, washed and eluated. RNA was extracted
with 30 μl RNase-free water and the RNA content was
measured with the NanoDrop ND-1000 Spectrophotom-
eter (NanoDrop Technologies, Wilmington, USA). The
RNA integrity was validated with the RNA 6000 Nano
LabChip® kit on the Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA). The Agilent 2100
Expert software generates so-called RNA Integrity Number
(RIN) which is an accepted quality criterion for isolated
RNA [44]. The RNA samples were stored at -80°C up to
cDNA synthesis.
First Strand cDNA Synthesis
cDNA synthesis was performed with the Transcriptor First
Strand cDNA Synthesis Kit (Roche Applied Science, Penz-
berg, Germany) using 1 μg RNA in reaction. Kit-included
random hexamer primers were applied for first strand
cDNA synthesis after following procedure: 10 min at
25°C for primer annealing, 30 min at 55°C for reverse
transcription step, 5 min at 85°C for inactivation of Tran-
scriptor Reverse Transcriptase, then cooling on ice. The
cDNA volume amounted to 20 μl. Tubes were stored at -
20°C up to subsequent PCR. All cDNA samples were 1:5
diluted with RNase-free water for use as template in real-
time PCR.
Real-Time PCR
Real-time PCR was performed with the LightCycler Instru-
ment (Roche). For relative mRNA quantification of target
gene (ADAM9) two stably expressed reference genes, TBP
(TATA box binding protein) and PPIA (Peptidyl isomerase
A) were additionally determined [45]. The PCR reaction
volumes for both reference genes were 10 μl and 20 μl for
the target gene. All PCR reaction mixes included 1 μl
diluted cDNA. The PCR run conditions for the TBP mRNA
quantification were the same as described before [46]. For
the reference gene PPIA and the target gene ADAM9 the
PCR methods were also described previously [45]. The
used primer/probe sequences (in 5'-3' direction) for
ADAM9 mRNA quantification were as follows: forward
primer: ggtgacagatttggcaattgtg, reverse primer: ttgtgccttcgt-
taaccatcc, donor probe: acgcctagtcgaggcaccaaatgttg-6Fl
Table 1: Associations (χ2-tests/Fischers exact test) between the protein expression of ADAM9 in renal cell cancer and clinico-
pathological parameters (percentages in brackets)
Total low ADAM9 high ADAM9 p-value
All cases 108 (100) 71 (65.7) 37 (34.3)
Age 0.225
≤ 62 59 (54.6) 42 (71.2) 17 (28.8)
> 62 49 (45.4) 29 (59.2) 20 (40.8)
Histology < 0.001
Clear cell 86 (79.6) 65 (75.6) 21 (24.4)
chromophobe 5 (4.6) 2 (40.0) 3 (60.0)
Papillary 17 (15.7) 4 (23.4) 13 (76.5)
pT-status 0.104
pT1 54 (50.0) 40 (74.1) 14 (25.9)
pT2/3/4 54 (50.0) 31 (57.4) 23 (42.6)
pN-status* 0.022
pN0 51 (47.2) 36 (70.6) 15 (29.4)
pN1 12 (11.1) 4 (33.3) 8 (66.7)
Grading 0.002
G 1 11 (10.2) 11(100) 0 (0)
G 2 75 (69.4) 50 (66.7) 25 (33.3)
G 3/4 22 (20.4) 10 (45.5) 12 (54.5)
Residual tumour status# 0.073
R0 78 (72.2) 56 (71.8) 22 (28.2)
R1/2 15 (13.9) 7 (46.7) 8 (53.3)
Metastasis 0.014
M0 85 (78.7) 61 (71.8) 24 (28.2)
M1 23 (21.3) 10 (43.5) 13 (56.5)
* 45 cases were pNx
# 15 cases were RxBMC Cancer 2008, 8:179 http://www.biomedcentral.com/1471-2407/8/179
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and the acceptor probe: Cy5.5-gtgtggatttccagctaggatcagat-
gttcc-P. The cDNA amplification was performed with the
ready-to-use LightCycler® FastStart DNA MasterPLUS Hyb-
Probe (Roche). Final reaction concentrations of both
primers were 0.5 μmol/l and the concentration for the
donor/acceptor probes were 0.2 μmol/l each. The PCR
setup was: activation of FastStart Taq DNA Polymerase at
95°C for 15 min, followed by 45 cycles of denaturation at
95°C for 10 s, annealing at 62°C for 30 s and elongation
at 72°C for 30 s. The temperature transition rate was in
each cycle 20°C/s. The fluorescence detection was gained
after each annealing step and data was evaluated by the
method of second derivative maximum with the LightCy-
cler Software 3.5 (Roche). To reduce the inter-run variabil-
ity, the paired samples of non-malignant and malignant
tissue areas were measured in one PCR run. Calibration
curves for all three genes were generated with pooled
cDNA. PCR efficiencies were calculated from cDNA dilu-
tion curves of pooled cDNA and amounted to 1.84 for
PPIA, to 1.88 for TBP and to 1.95 for ADAM9. Each PCR
run included a cDNA with known expression level and
was used as standard for the quantification of the
unknown samples calculated by LightCycler Software Ver-
sion 3.5. Another pooled cDNA was used as run-to-run
precision control. For relative quantification of ADAM9
mRNA the expressions were related to geometric mean of
the two reference genes PPIA and TBP [47].
Immunohistochemistry
Formalin fixed paraffin embedded tissue was freshly cut
(3 μm). The sections were mounted on Superfrost slides
(Menzel Gläser, Braunschweig, Germany), dewaxed with
xylene and gradually hydrated. Antigen retrieval was
achieved by pressure cooking in 0.01 M citrate buffer for
5 min. The primary ADAM9-antibody (goat polyclonal,
AF949, R&D Systems, Wiesbaden, Germany) [20] was
diluted 1:50 using a background reducing dilution buffer
(Dako, Glostrup, Denmark) and incubated at room tem-
perature for 1 hour. Detection took place with the REAL™
EnVision™ System (Dako) according to the manufac-
turer's instructions. Diaminobenzidin (Sigma-Aldrich,
Munich, Germany) served as chromogen. Afterwards the
slides were briefly counterstained with haematoxylin and
mounted. As negative controls a set of sequential TMA
slides was processed omitting the primary antibody to
exclude unspecific background. To evaluate intratumoural
heterogeneity of ADAM9 expression we additionally
stained 10 conventional tissue slides with RCC.
Evaluation of the immunohistochemical stainings
The immunostainings were evaluated by two genitouri-
nary pathologists blinded for patient outcome using a
multiheaded microscope. The staining intensity was eval-
uated with a four-tier grading system (0 = negative, 1 =
weak, 2 = moderate and 3 = strong staining intensity). We
used a 10% threshold to determine positivity. To deline-
ate between low and high levels of ADAM9 expression the
tumours with strong ADAM9 expression were grouped
against those with none to moderate staining intensity.
Additionally, we compared the difference of the ADAM9
immunoreactivity in the two tumour spots from each
case.
Statistical analysis
Statistical analysis was performed using SPSS, version
14.0. Fisher's exact tests, χ2-tests and Kruskal-Wallis tests
were applied to assess the statistical significance of the
associations between ADAM9 expression and clinico-
pathological parameters. Rank correlations were calcu-
lated according to Spearman. Univariate survival analysis
was carried out according to Kaplan-Meier, differences in
survival curves were assessed with the Log rank test. Cox
regression model was used for multivariate survival anal-
yses. P values < 0.05 were considered significant.
Results
RNA quality and quantitative RT-PCR
RIN values of isolated RNA from kidney tissue samples
ranged from 7.0 to 10.0 (mean = 8.7, SD = 0.80) reflecting
the high quality and integrity of the RNA. The normalized
ADAM9 expression was significantly higher in cancer than
in normal tissue samples (mean change fold 2.7, range:
0.9–12.6; p < 0.0001; Figure 1). In three out of the 30
matched pairs ADAM9 mRNA expression was higher in
the normal renal tissue. Significant associations between
the mRNA expression of ADAM9 in RCC and clinico-
pathological parameters (tumour stage, grading, nodal
status, metastasis, histologic type and residual tumour sta-
tus) could not be demonstrated (all p > 0.05).
ADAM9 immunostaining in normal and malignant renal 
tissues
ADAM9 was expressed in malignant and non-malignant
renal epithelia (Figure 2). The generally cytoplasmic
immunoreactivity of ADAM9 was accentuated in the
luminal part of the non-cancerous tubular epithelia and
was particularly pronounced in the proximal tubules in
comparison to distal tubules, which showed a weaker and
more diffuse staining pattern. Glomerula and stromal
cells were negative.
In renal cell carcinomas, a cytoplasmic and membranous
staining was seen in all tumour subtypes, with papillary
carcinomas displaying the strongest cytoplasmic immu-
noreactivity. The distribution of the ADAM9 staining is
summarized in Table 2. One case swam off the slide dur-
ing immunostaining. Although strong protein expression
was found much more frequently in the tumour than in
the normal tissue, these differences remained insignifi-
cant according to the Wilcoxon signed rank test (p =BMC Cancer 2008, 8:179 http://www.biomedcentral.com/1471-2407/8/179
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0.367). The median of both tissue types was 2 and the
mean 1.95 (normal) and 2.04 (tumour) respectively.
Matched normal tissue was available in 104 cases. It is
interesting to note that none of the normal tissues and
only two of the cancer cases were completely negative for
ADAM9.
Since the TMA was constructed to represent two spots of
tumour from each case sampled from different tumour
areas, differences of immunoreactivity between these
spots can be used to estimate intratumoural heterogeneity
of expression. We found ADAM9 staining completely
equal both tumour spots in 91.7% (98/107; in one case
only one spot had sufficient tumour tissue), which we
consider a high rate of concordance. The additionally
immunostained conventional tissue slides supported this
estimation of a homogenous ADAM9 expression in
tumour tissue. This is an important observation for it
allows the use of TMAs for evaluation of ADAM9 in renal
cell cancer.
ADAM9 expression, clinico-pathological correlations and 
disease free survival times
In bivariate Spearman's rank correlations the ADAM9 pro-
tein expression in renal cancer correlated with the tumour
grade, patient age and positive tumour resection status
(R1) (Table 3). Additionally performed Kruskal-Wallis
tests further confirmed the non-significant associations of
ADAM9 expression with M-status (p = 0.096), nodal sta-
tus (p = 0.098), whereas residual tumour status was of
borderline significance (p = 0.050). In the χ2-tests higher
ADAM9 protein expression was significantly associated
tumour grade, distant metastasis, positive nodal status
Table 2: Distribution of ADAM9 staining in normal and 
malignant renal tissue (percentages in brackets)
Staining ADAM9 Normal ADAM9 Cancer
Negative 0 (0) 2 (1.9)
1+ 9 (8.3) 29 (26.9)
2+ 91 (84.3) 40 (37.0)
3+ 4 (3.7) 37 (34.3)
ADAM9 mRNA expression Figure 1
ADAM9 mRNA expression. ADAM9 mRNA expression 
of matched pairs of non-malignant and malignant renal tissue 
samples was normalized to the geometric mean of the two 
reference genes PPIA and TBP. For most cases mRNA levels 
of the renal cell cancers laid above those of the normal tissue 
standard.
non-malignant malignant
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ADAM9 immunohistochemistry Figure 2
ADAM9 immunohistochemistry. A-C Clear cell carci-
nomas with weak (A), moderate (B) and strong (C) ADAM9 
protein expression. D/E Papillary (D) and chromophobe (E) 
renal cell carcinoma with strong ADAM9 expression. F Nor-
mal renal tissue with weak (F1) and strong (F2) ADAM9 
expression.
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and papillary as well as chromophobe histologic subtype
(Table 1).
In univariate analyses (Kaplan-Meier) of patient survival
the clinico-pathological characteristics pT-status, grading,
nodal status, residual tumour status (R0 vs. R1) and dis-
tant metastasis (M0 vs. M1) reached statistical significance
(Table 4). Histologic subtype and age were no prognosti-
cators of patient survival (data not shown). Higher
ADAM9 expression in renal cancer was significantly asso-
ciated with shortened survival times (Table 4 & Fig. 3, p =
0.026). The Cox multivariate survival analysis revealed no
independent prognostic value for ADAM9 expression and
tumour grading whereas pT-and pM-stage remained
highly significant (Table 5). The univariate prognostica-
tors pN- and residual tumour status were not included in
the Cox regression model since because of missing data
this would have led to a significant drop in the number of
cases for this analysis.
Table 4: Univariate survival analysis (Kaplan-Meier)
Characteristic No. of cases No. of events Two-year survival rate (± SE) in % p-value
ADAM9 expression 0.026
low 71 10 85.9 ± 4.1
high 37 12 70.3 ± 7.5
pT-status < 0.001
pT1 54 2 96.3 ± 2.6
pT2/3/4 54 20 64.8 ± 6.5
Grading 0.001
G 1 11 0 -
G 2 75 12 85.3 ± 4.1
G 3/4 22 10 54.5 ± 10.6
pN-status 0.001
pN0 51 10 80.4 ± 5.6
pN1+ 12 8 41.7 ± 14.2
Residual tumour < 0.001
R0 78 10 87.2 ± 3.8
R1/2 15 8 46.7 ± 12.9
Metastasis < 0.001
M0 85 8 90.6 ± 3.2
M1 23 14 43.5 ± 10.3
Survival times of patients with renal cancer according to clinico-pathological characteristics and ADAM9 protein expression.
Table 3: Correlation of ADAM9 protein expression in renal cell cancer with clinical/tumour-parameters
ADAM9 ADAM9 N pT-status Grading pN-status R-status M-status Age
CC 0.107 0.166 0.239 0.212 0.206 0.212 0.219
P 0.282 0.085 0.013 0.096 0.047 0.076 0.023
N 104 108 108 63 94 71 108
CC = Spearman's rank correlation coefficient, p = two sided significance, N = number of cases, ADAM9 N = ADAM9 expression in normal tissue, 
R-status = residual tumour status (R0/R1+), M-status = Metastasis (M0/M1).BMC Cancer 2008, 8:179 http://www.biomedcentral.com/1471-2407/8/179
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Discussion
Several ADAMs, including ADAM9, have been described
in various solid tumours on mRNA and/or protein level in
and have often been associated with adverse prognostic
parameters or shorter patient survival [18-21,23,25-
32,48-50]. Our results are in line with this notion and
demonstrate a prognostic value of ADAM9 for renal cell
cancer at least in the univariate analysis. Although the
whole model of the Cox analysis was significant, ADAM9
itself remained insignificant under multivariate condi-
tions. Probably this might have been due to the strong
association of ADAM9 expression with positive pM- status
and higher tumour grade. Surprisingly, the histological
tumour grade remained insignificant as well. This suggests
that the cohort might have been not large enough to eval-
uate significance for these parameters, although pT-status
and metastasis status could be verified as independent
prognosticators. If nodal status and residual tumour status
were included in the Cox analysis, all parameters would
have lost their significance, probably caused by the
strongly decreased number of cases in that analysis (data
not shown).
ADAM9 was mainly expressed in the proximal part of the
nephron. This is in line with a high expression of ADAM9
in clear cell and papillary carcinomas, which are thought
to originate from that region. Interestingly also three of
the five chromophobe RCC included showed a high
ADAM9 expression, although this tumour type is thought
to rather originate from the distal nephron. In our study
we could not demonstrate a statistically significant up-reg-
ulation of ADAM9 protein expression in RCC in compar-
ison to normal renal tissue. This is not in line with our
results from the separate mRNA-sample cohort, where
only 10% of the normal tissue displayed higher ADAM9
expression than the tumour. Possibly, posttranscriptional
processes could be responsible for this discrepancy. On
the other hand, only 4% of normal tissues showed a
strong ADAM9 protein expression in comparison to 34%
of the tumours, which clearly supports the notion that
ADAM9 is up-regulated on protein level in a larger pro-
portion of renal cell carcinomas.
These findings are generally coherent with results from
previous studies on ADAM9 in solid tumours which evi-
dence the role of ADAM9 in tumourigenesis and tumour
progression [22,25,51,52]. Functionally, blocking of
ADAM9 with specific antibodies resulted in inhibited cell
growth of gastric cancer cell lines [18]. Over-expression of
ADAM9 in lung cancer cell lines resulted in enhanced
invasiveness and was significantly associated with brain
metastases [50]. In melanoma, ADAM9 is up-regulated in
vivo at the invasion front [27]. In our study, the significant
associations of ADAM9 with prognostically adverse con-
ventional tumour parameters (positive nodal status, dis-
tant metastasis, residual tumour in the resection margins
and higher tumour grade) are clearly in line with these
findings.
Interestingly, ADAM9 was also found in most (13 of 17)
papillary renal cell carcinomas. Although the number of
cases with this subtype of RCC was small in our cohort,
this information might be of adjunct diagnostic use for
the assessment of renal cell carcinomas.
Conclusion
In conclusion our results support the notion of ADAM9 to
be associated with more aggressive tumours and unfa-
vourable outcome. ADAM9 protein expression was signif-
icantly associated with shortened survival times but failed
significance in a multivariate analysis. To further assess a
possible independent prognostic role and the usefulness
of ADAM9 for the sub classification of RCC, further vali-
dation using larger tumour cohorts is clearly warranted.
Table 5: Multivariate survival analysis
Variable Relative Risk 95% CI p-value
ADAM9 1.081 0.433–2.696 0.868
pT-status 6.820 1.462–31.827 0.015
Grading 1.060 0.434–2.589 0.899
Metastasis 1.496 1.534–13.177 0.006
Cox regression model, n = 108: ADAM9 and clinico-pathological 
characteristics grouped as in Table 4. CI = confidence interval.
Kaplan-Meier survival curves for ADAM9 Figure 3
Kaplan-Meier survival curves for ADAM9. The number 
of events (deaths) is given in brackets. Tumours with high 
ADAM9 expression (bold line) revealed significantly short-
ened patient survival times if compared to those with low 
ADAM9 expression (dotted line).
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